AstraZeneca (NYSE: AZN) awards deferred bonus shares to leaders

Rhea-AI Filing Summary

AstraZeneca PLC reported that share awards granted under its AstraZeneca Deferred Bonus Plan for 2022 performance vested on 4 March 2026 for senior executives. These awards reflect portions of prior annual bonuses that were deferred into ordinary shares and held for a three-year period.

On vesting, Chief Executive Officer Pascal Soriot acquired 14,967 ordinary shares and Chief Financial Officer Aradhana Sarin acquired 4,863 ordinary shares, both for nil consideration. For tax purposes, the fair market value at vest was 14,932 pence per ordinary share, based on the closing price on the last trading day before vesting.

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of March 2026 

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Director/PDMR Shareholding

 6 March 2026

Transactions by Persons Discharging Managerial Responsibilities

AstraZeneca PLC (the Company) announced that, on 4 March 2026, awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) vested to certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) under the terms of the AstraZeneca Deferred Bonus Plan (AZDBP).

The AZDBP award was granted on 4 March 2023, following the deferral of a portion of each PDMR's annual bonus in respect of 2022 performance into Ordinary Shares, and vested on completion of the three-year holding period.

Following the reinvestment of dividends accrued during the deferral period of the AZDBP award, and the withholding of shares to satisfy certain tax obligations arising on vesting, the PDMRs' beneficial interests in Ordinary Shares changed as detailed in the table below:

PDMR	Position	Ordinary Shares acquired
Pascal Soriot	Executive Director and Chief Executive Officer	14,967
Aradhana Sarin	Executive Director and Chief Financial Officer	4,863

For tax purposes, the fair market value of an Ordinary Share at vest of the AZDBP award was 14,932 pence, being the closing price on the last trading day preceding the vesting.

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Pascal Soriot
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292
b)	Nature of the transaction	Acquisition of Ordinary Shares pursuant to a vesting under the AstraZeneca Deferred Bonus Plan, for nil consideration.
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		0	14,967
d)	Aggregated information - Aggregated volume - Price	Not applicable - single transaction
e)	Date of the transaction	4 March 2026
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Aradhana Sarin
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292
b)	Nature of the transaction	Acquisition of Ordinary Shares pursuant to a vesting under the AstraZeneca Deferred Bonus Plan, for nil consideration.
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		0	4,863
d)	Aggregated information - Aggregated volume - Price	Not applicable - single transaction
e)	Date of the transaction	4 March 2026
f)	Place of the transaction	Outside a trading venue

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 06 March 2026

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary

FAQ

What executive share awards did AstraZeneca (AZN) report in this document?

AstraZeneca reported the vesting of deferred bonus share awards for senior executives. CEO Pascal Soriot acquired 14,967 ordinary shares and CFO Aradhana Sarin acquired 4,863 ordinary shares, reflecting portions of their 2022 bonuses deferred into shares under the AstraZeneca Deferred Bonus Plan.

What is the AstraZeneca Deferred Bonus Plan (AZDBP) mentioned for AZN?

The AstraZeneca Deferred Bonus Plan allows a portion of executives’ annual bonuses to be deferred into ordinary shares. Awards referenced here were granted on 4 March 2023 for 2022 performance and vested after a three-year holding period, resulting in share acquisitions for the CEO and CFO.

When did the AstraZeneca (AZN) deferred bonus share awards vest?

The deferred bonus share awards vested on 4 March 2026. These awards were originally granted on 4 March 2023 under the AstraZeneca Deferred Bonus Plan, following deferral of part of executives’ 2022 bonuses into shares, and became exercisable after a three-year holding period.

At what value were AstraZeneca (AZN) shares measured for tax on vesting?

For tax purposes, the fair market value of an AstraZeneca ordinary share at vesting was 14,932 pence. This value was based on the closing share price on the last trading day before the deferred bonus awards vested on 4 March 2026.

Did AstraZeneca (AZN) executives pay for the shares acquired on vesting?

No, the executives did not pay cash for the vested shares. The document states the acquisitions were for nil consideration, with shares delivered following vesting of deferred bonus awards and some shares withheld to cover tax obligations arising on vesting.

How were taxes handled on the AstraZeneca (AZN) deferred bonus vesting?

Taxes arising from the vesting were settled through withholding of a portion of the vested shares. The company notes that shares were withheld to satisfy certain tax obligations, while remaining shares reflected the executives’ beneficial interests after vesting and dividend reinvestment adjustments.